Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + tislelizumab + anlotinib in advanced esophageal cancer (Phase II, single-arm)
ChiCTR2500110497Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, tislelizumab and anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Progression-free survival and Overall survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tucidinostattislelizumabanlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500110497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110497.